An observational study in Osteosarcoma, Transcriptome and Tumor Microenvironment, sponsored by Peking University People's Hospital. Not yet recruiting. Open to participants aged 8 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-24.
Sponsored by Peking University People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.
Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, and was the 22nd registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 12–65
Peking University People's Hospital · Sites in China
Ages 14–70
Peking University People's Hospital · Sites in China
Ages 18–60
Peking University People's Hospital · Sites in China
Ages 12+
By country, each count listing its studies:
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 8 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8
First in 2015; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 99 observational studies indexed under Osteosarcoma.
Median enrollment 56 across the 12 interventional studies, 100 across the 14 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
1 of the studies in Osteosarcoma by Peking University People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479732Peking University People's HospitalApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | 2027-03-05 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Osteosarcoma by Peking University People's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.
Initially treated osteosarcoma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Chemotherapy
Drug: Chemotherapy
Drug: Chemotherapy
Drug: Chemotherapy
Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
Event-free Survival (EFS)
From biopsy to progression/last follow-up
Time frame: 2 year
Event-free Survival (EFS) for the second time
From first progression to the second progression/last follow-up
Time frame: 2 year
Correlation with some DNA target expression
Time frame: 1 year
No study locations are listed for this record.
Plan to share: No
Start is estimated for Mar 2025; primary completion for Mar 2026, 12 months later.
Of 41 observational studies under Osteosarcoma, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 228. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →